MET and hepatocellular carcinoma: In hepatocellular carcinoma, although encouraging results were reported in phase II studies [47,48,49], the phase III trial failed to show an improvement in the overall survival compared with the placebo in patients with c-MET-positive advanced hepatocellular cancer (HCC), casting doubt on the role of MET inhibition as a viable therapeutic strategy [50,51].